Christopher Mutz Ani Pharmaceuticals Inc (ANIP) insider trading activity

Christopher Mutz is HEAD OF RARE DISEASE of ANI PHARMACEUTICALS INC. Currently has a direct ownership of 111,317 shares of ANIP, which is worth approximately $6.96 Million. The most recent transaction as insider was on Mar 07, 2025, when has been sold 2,874 shares (Common Stock) at a price of $60.62 per share, resulting in proceeds of $174,221. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 111K

44.99% 3M change

30.54% 12M change

Total Value Held $6.96 Million

Christopher Mutz Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 07 2025	SELL Payment of exercise price or tax liability	$174,221 $60.62 p/Share	2,874 Reduced 2.52%	111,317 Common Stock
Feb 28 2025	SELL Payment of exercise price or tax liability	$78,909 $61.89 p/Share	1,275 Reduced 1.1%	114,191 Common Stock
Feb 15 2025	SELL Payment of exercise price or tax liability	$69,761 $58.92 p/Share	1,184 Reduced 1.02%	115,466 Common Stock
Feb 14 2025	SELL Payment of exercise price or tax liability	$86,789 $58.92 p/Share	1,473 Reduced 1.25%	116,650 Common Stock
Feb 12 2025	BUY Grant, award, or other acquisition	-	41,346 Added 25.93%	118,123 Common Stock
Nov 15 2024	SELL Open market or private sale	$375,050 $57.7 p/Share	6,500 Reduced 7.81%	76,777 Common Stock
May 21 2024	SELL Open market or private sale	$123,220 $61.61 p/Share	2,000 Reduced 2.35%	83,277 Common Stock
Mar 07 2024	SELL Payment of exercise price or tax liability	$140,758 $66.71 p/Share	2,110 Reduced 2.41%	85,277 Common Stock
Mar 05 2024	SELL Open market or private sale	$330,000 $66.0 p/Share	5,000 Reduced 5.41%	87,387 Common Stock
Feb 29 2024	SELL Payment of exercise price or tax liability	$86,279 $67.67 p/Share	1,275 Reduced 1.36%	92,387 Common Stock
Feb 15 2024	SELL Payment of exercise price or tax liability	$72,570 $57.55 p/Share	1,261 Reduced 1.33%	93,662 Common Stock
Feb 14 2024	BUY Grant, award, or other acquisition	-	31,316 Added 24.81%	94,923 Common Stock
Nov 10 2023	SELL Open market or private sale	$157,410 $52.47 p/Share	3,000 Reduced 4.5%	63,607 Common Stock
Mar 07 2023	SELL Payment of exercise price or tax liability	$84,125 $44.23 p/Share	1,902 Reduced 4.81%	37,660 Common Stock
Feb 28 2023	BUY Grant, award, or other acquisition	-	28,947 Added 30.29%	66,607 Common Stock
Feb 15 2023	SELL Payment of exercise price or tax liability	$58,191 $45.04 p/Share	1,292 Reduced 3.16%	39,562 Common Stock
Apr 27 2022	BUY Grant, award, or other acquisition	-	6,476 Added 13.68%	40,854 Common Stock
Mar 24 2022	BUY Grant, award, or other acquisition	-	19,428 Added 36.11%	34,378 Common Stock
Feb 15 2022	SELL Payment of exercise price or tax liability	$47,656 $40.25 p/Share	1,184 Reduced 7.34%	14,950 Common Stock
Feb 15 2021	BUY Grant, award, or other acquisition	-	16,134 Added 50.0%	16,134 Common Stock

Christopher Mutz

HEAD OF RARE DISEASE

Baudette, MN

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ANIP shares.

Notify only if

Value

Insider Trading

Get notified when an Ani Pharmaceuticals Inc insider buys or sells ANIP shares.

Notify only if

Operation

Value

Type

News

Receive news related to ANI PHARMACEUTICALS INC

Track Activities on ANIP

Account